Quick Answer
FILANA THERAPEUTICS, INC. reported Research And Development Expense of $26.59 million for the year ending 2025.
- FILANA THERAPEUTICS, INC. showed a decrease of -61.8% in Research And Development Expense from 2024 to 2025.
- This data is from FILANA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2009 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $2.25 million | Q3 2010: $2.36 million | Q1 2011: $2.18 million | Q2 2011: $2.39 million | Q3 2011: $2.02 million | Q1 2012: $1.61 million | Q2 2012: $1.52 million | Q3 2012: $2.38 million | Q1 2013: $1.18 million | Q2 2013: $1.14 million | Q3 2013: $1.44 million | Q1 2014: $2.15 million | Q2 2014: $1.94 million | Q3 2014: $2.12 million | Q1 2015: $1.14 million | Q2 2015: $1.99 million | Q3 2015: $2.36 million | Q1 2016: $3.60 million | Q2 2016: $1.59 million | Q3 2016: $2.66 million | Q1 2017: $1.39 million | Q2 2017: $3.06 million | Q3 2017: $1.62 million | Q1 2018: $1.07 million | Q2 2018: $1.46 million | Q3 2018: $1.46 million | Q1 2019: $574.0 thousand | Q2 2019: $308.0 thousand | Q3 2022: $18.53 million | Q1 2023: $22.12 million | Q2 2023: $24.97 million | Q3 2023: $23.60 million | Q1 2024: $16.23 million | Q2 2024: $15.20 million | Q3 2024: $17.68 million | Q1 2025: $13.67 million | Q2 2025: $5.12 million | Q3 2025: $3.96 million.
- Over the full 15 years of available data (2009 to 2025), FILANA THERAPEUTICS, INC.'s Research And Development Expense has grown by 26.3%.
- Historical annual values: Fiscal year 2025: $26.59 million | Fiscal year 2024: $69.64 million | Fiscal year 2023: $89.42 million | Fiscal year 2022: $68.03 million | Fiscal year 2021: $24.81 million | Fiscal year 2018: $2.97 million | Fiscal year 2017: $7.62 million | Fiscal year 2016: $9.18 million | Fiscal year 2015: $9.10 million | Fiscal year 2014: $7.31 million | Fiscal year 2013: $4.92 million | Fiscal year 2012: $7.61 million | Fiscal year 2011: $8.30 million | Fiscal year 2010: $15.75 million | Fiscal year 2009: $21.06 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: